GlaxoSmithKline
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, GlaxoSmithKline sits in the top decile of US sponsors by registered trial count (#17 of 15,742 sponsors by registered trial count).
GlaxoSmithKline: 1,345 sponsored US clinical trials, 50 recruiting.
GlaxoSmithKline sponsors 1,345 registered US clinical trials on ClinicalTrials.gov, 50 of them currently recruiting, and 1,130 completed. 486 of these trials are in Phase 3-4 (later-stage) and 791 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Pulmonary Disease, Chronic Obstructive, with 30 trials.
Top-decile sponsor footprint
GlaxoSmithKline ranks in the top decile of sponsors by registered trial count (#17 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,130 of 1,249 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,345 total, page 4 of 27
A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Adults Aged 60 Years and Above
NCT05059301
A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension
NCT04880031
Phase 1 Study of GSK3228836 Pharmacokinetics in Participants With Hepatic Impairment
NCT04971928
Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)
NCT04950127
A Study on the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers
NCT04980391
A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults
NCT04886154
An Epidemiological Study to Assess Performance of Using Healthcare Tools to Understand Genital Herpes Simplex Virus-2 (HSV-2) in Patients ≥ 18 Years of Age in the United States and Europe.
NCT04950712
Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above
NCT04886596
Molecular Disease Characterization Initiative (MDCI)
NCT04772053
Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype
NCT04719832
A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older
NCT04789577
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2
NCT06790303
Sun Protection Factor (SPF) Determination of Two Sunscreen-Containing Lip Balms
NCT04749459
A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years
NCT04762511
A Study of the Safety of and Immune Response to Varying Doses of a Vaccine Against COVID-19 in Healthy Adults
NCT04758962
A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype
NCT04718103
Study of Sequential GSK3228836 and Peginterferon Treatment in Participants With Chronic Hepatitis B (CHB)
NCT04676724
A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype
NCT04718389
Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine
NCT04707391
Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin
NCT04549363
Comparison of Daprodustat Formulations Produced by Two Methods of Manufacture for Bioequivalence and Dissolution in Healthy Participants
NCT04640311
Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 OA Investigational Vaccine in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study
NCT04657198
A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers
NCT04605159
Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
NCT04581824
A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer
NCT04349280
A Mechanistic Study of GSK3228836 With Fine Needle Aspiration (FNA) in Participants With Chronic Hepatitis B
NCT04544956
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Participants With Diabetic Macular Edema
NCT04292912
Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age
NCT04318548
Drug-drug Interaction Study of Gepotidacin
NCT04493931
Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults
NCT04502693
Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT04428333
A Study of GSK3228836 in Participants With Chronic Hepatitis B (CHB)
NCT04449029
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Melrilimab (GSK3772847) in Healthy Participants
NCT04366349
Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease
NCT04376684
Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA)
NCT04333147
Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI)
NCT04187144
Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT04128696
A Study of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Diphtheria, Pertussis and Tetanus (Tdap) Viruses Followed by a 2nd Dose of the RSV Vaccine to Healthy Non-Pregnant Women
NCT04138056
Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants
NCT04126213
Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors
NCT04134728
Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level
NCT04133909
A Study Evaluating Efficacy and Safety of Gepotidacin Compared With Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea
NCT04010539
A Study to Evaluate Efficacy and Safety of Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection (UTI)
NCT04020341
A Clinical Study Investigating the Efficacy of a Stannous Fluoride Dentifrice in Improving Gingival Health After Twice Daily Use for 3 Weeks
NCT04050722
Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer
NCT02964507
Pharmacokinetics of Gepotidacin Tablets in Adults and Adolescents Subjects
NCT04079790
A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Experimental Rabies Vaccine in Healthy Adults
NCT04062669
Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)
NCT03457701
Safety Study of 2 Formulations of GSK's Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
NCT03954743
Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)
NCT03970837
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 440 |
| Phase 2 | 351 |
| Phase 3 | 377 |
| Phase 4 | 109 |
Therapeutic Areas
What is open in the GlaxoSmithKline pipeline
50 recruiting of 1,345 indexed (4% open); 1,130 completed (84%).
Phase mix: 486 late (III/IV) vs 791 early (I/II) (early-phase heavy).
Top condition: Pulmonary Disease, Chronic Obstructive (30 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
GlaxoSmithKline: open-pipeline peers nationwide
Peers matched on 1,345 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
GlaxoSmithKline sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,345 trials (± recruiting share)
- Eli Lilly and Company · 1,341 trials · 9% recruiting
- University of Michigan · 1,327 trials · 13% recruiting
- Novartis Pharmaceuticals · 1,375 trials · 8% recruiting
- AstraZeneca · 1,285 trials · 12% recruiting
Sponsors near 4% open enrollment (± trial volume)
- Stryker Orthopaedics · 4% recruiting · 27 trials
- US Oncology Research · 4% recruiting · 27 trials
- Otsuka Pharmaceutical Development & Commercialization · 4% recruiting · 221 trials
- Teva Branded Pharmaceutical Products R&D · 4% recruiting · 167 trials
Related
What to do with this GlaxoSmithKline page
1,345 registered trials is a research-attention snapshot, not an endorsement of GlaxoSmithKline or any single study.
- 50 of GlaxoSmithKline's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Pulmonary Disease, Chronic Obstructive is the condition GlaxoSmithKline studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Pulmonary Disease, Chronic Obstructive trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
GlaxoSmithKline pipeline card: 1,345 registered trials from official public datasets.Report a data error.